SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing intense selling pressure following a quarterly report that revealed significant headwinds in China and ongoing concerns regarding the impact of tariffs on margins. Investors are actively debating the company's long-term relevance and the effectiveness of management's turnaround efforts, with many expressing frustration over the stock's persistent decline compared to its historical performance.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussion as investors debate its long-term potential amid significant leadership changes and a shift toward U.S.-based institutional operations. While some users express frustration over stagnant price action and recent market lows, a vocal segment of the community remains focused on the project's real-world utility, recent regulatory clarity, and its ongoing efforts to scale institutional adoption.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF ($NASA) is generating intense debate, with traders speculating it could mimic the high-volatility price action of other niche space-sector funds. While some investors are optimistic about its strategic exposure to industry leaders like SpaceX, critics are raising concerns regarding its low assets under management and the transparency of its underlying private holdings.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently at the center of market volatility as investors weigh conflicting reports regarding potential developments with SpaceX and geopolitical tensions, while closely monitoring technical support levels after a recent bounce. Community sentiment remains deeply divided between those betting on ecosystem synergy and long-term AI-driven growth and those expressing skepticism over valuation and the potential for a deeper correction.

Ganymede

Ganymede is drawing attention as market participants highlight its clean structural formation and consistent buyer interest, fueling community optimism about its potential for growth. Traders are actively discussing the token's quiet momentum and controlled price action, viewing current levels as a favorable accumulation phase.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is surging following the FDA approval of EMPAVELI for the treatment of rare kidney diseases, marking a significant milestone that investors hope will validate the company's immunology pipeline. The community is actively discussing the stock's potential for a broader recovery, with many bulls focusing on the commercial opportunity in the nephrology space and speculating on whether this momentum might finally trigger long-awaited interest from potential acquirers.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as a strategic proxy for SpaceX, driven by market speculation surrounding the rocket manufacturer's potential IPO and the ongoing monetization of EchoStar's valuable spectrum assets. Community discourse is heavily focused on the stock's intrinsic value and its large equity stake in SpaceX, with many investors debating the impact of upcoming financial results and regulatory developments on future price appreciation.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is currently a major focus for market participants as they weigh a strong delivery pace against broader sector volatility driven by rising oil prices and geopolitical tensions. The community is sharply divided, with bulls pointing to the company's expanding infrastructure and production milestones as indicators of long-term value, while bears emphasize the stock's historical underperformance and ongoing concerns regarding profitability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant market attention as traders and investors await crucial Phase 3 clinical data for its lead drug, sonelokimab, to be presented at an upcoming dermatology conference. The stock is currently experiencing heightened volatility and speculative trading, fueled by persistent buyout rumors involving major pharmaceutical players and a community sentiment heavily focused on the stock's potential for a short squeeze.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors focus on its institutional-grade DeFi infrastructure, with recent activity bolstered by significant token acquisitions from World Liberty Financial and continued optimism around the upcoming Aave V4 architecture. Community sentiment remains largely bullish, centered on AAVE's fundamental value, revenue-generating capabilities, and its role as a key player in bridging decentralized and traditional finance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Begins Coverage on Envoy Medical (NASDAQ:COCH)

HC Wainwright began coverage on Envoy Medical in a research report on Tuesday. They issued a "buy" rating and a $2.50 price objective for the company...

Envoy Medical, Inc. (NASDAQ:COCH) Short Interest Update

Envoy Medical, Inc. (NASDAQ:COCH - Get Free Report) was the target of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 804,479 shares...

Envoy Medical (COCH) to Release Quarterly Earnings on Tuesday

Envoy Medical (NASDAQ:COCH) will be releasing earnings before the market opens on Tuesday, April 7. (View Earnings Report at...

EXCLUSIVE: Envoy Medical Hits Trial Milestone For Cochlear Implant Designed To Work With Natural Ear

Envoy Medical completes enrollment for its Acclaim cochlear implant trial, a fully implanted device designed without external components.read more...

Insider Buying: Envoy Medical (NASDAQ:COCH) Major Shareholder Buys 18,750,000 Shares of Stock

Envoy Medical, Inc. (NASDAQ:COCH - Get Free Report) major shareholder Glen Taylor purchased 18,750,000 shares of the business's stock in a transaction that occurred on Thursday, February 12th. The...

Envoy Medical, Inc. (COCH) Upgraded to Buy: Here's Why

Envoy Medical, Inc. (COCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Envoy Medical, Inc. (COCH) Reports Q3 Loss, Misses Revenue Estimates

Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of -29.63% and -23.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Lags Revenue Estimates

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -5.00% and -10.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Envoy Medical, Inc. (COCH) Expected to Beat Earnings Estimates: Should You Buy?

Envoy Medical, Inc. (COCH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avanos Medical (AVNS) Q3 Earnings and Revenues Beat Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of +37.50% and +6.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Envoy Medical, Inc. is a hearing health company, which engages in providing medical technologies across the hearing loss spectrum. It focuses on designing, developing, and marketing fully implantable medical devices that improve hearing. The company was founded in 1995 and is headquartered in White Bear Lake, MN.

Envoy Medical Inc - Ordinary Shares - Class A

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

COCH
Envoy Medical Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest COCH News

COCHEnvoy Medical Inc - Ordinary Shares - Class A